NIH Consensus Development Conference on Genetic Testing for Cystic Fibrosis: April 14-16, 1997, Natcher Conference Center, National Institutes of Health, Bethesda, Md, Número 691

Portada
National Institutes of Health, Continuing Medical Education, 1997 - 107 páginas
 

Comentarios de usuarios - Escribir una reseña

No hemos encontrado ninguna reseña en los sitios habituales.

Términos y frases comunes

Pasajes populares

Página 23 - Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992; 90:1296-1301.
Página 20 - Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N. Engl. J. Med.
Página 27 - It will diminish the usual complaints of frequent, loose, foul movements, protuberant abdomen and excessive appetite, it will markedly reduce the incidence of rectal prolapse and possibly secondary fecal impaction which may result in intestinal obstruction."* "Schwachman, H.. Redmond. A. and Khaw. KT: "Studies in Cystic Fibrosis— Report of 130 Patients Diagnosed Under 3 Months of Age Over a 20-Year Period : Pediatrics.
Página 23 - Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis.
Página 9 - Program Analyst Office of Medical Applications of Research National Institutes of Health Bethesda, Maryland Suzanne W.
Página 9 - Branch National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda, Maryland KENNETH V.
Página 20 - A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994; 331:974-980.

Información bibliográfica